Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jiangxi Institute of Biological ProductsHKSE:06915 +1.33%23 Return-on-Tangible-Equity is 21.38% as of Dec. 2025, which is 10% above its 10-year median of 19.44. GuruFocus rates HKSE:06915 with a GF Score™ of 23/100. The stock has 3 warning signs investors should review. Among 898 Drug Manufacturers companies, Jiangxi Institute of Biological Products ranks better than 79.73% on this metric.
HKSE:06915'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 15.36 Med: 19.44 Max: 21.38
Current: 21.38
During the past 3 years, Jiangxi Institute of Biological Products's highest Return-on-Tangible-Equity was 21.38%. The lowest was 15.36%. And the median was 19.44%.
HKSE:06915's Return-on-Tangible-Equity is ranked better than 79.73% of 898
companies
in the Drug Manufacturers industry
Industry Median: 7.515
vs HKSE:06915: 21.38
Jiangxi Institute of Biological Products (HKSE:06915) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Jiangxi Institute of Biological Products Return-on-Tangible-Equity Related Terms
Jiangxi Institute of Biological Products Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangxi Institute of Biological Products Return-on-Tangible-Equity Chart
Jiangxi Institute of Biological Products Annual Data
Trend
Dec23
Dec24
Dec25
Return-on-Tangible-Equity
15.36
19.44
21.38
Jiangxi Institute of Biological Products Semi-Annual Data
Dec23
Dec24
Dec25
Return-on-Tangible-Equity
15.36
19.44
21.38
HKSE:06915 vs LLY, JNJ, ABBV: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - General subindustry, Jiangxi Institute of Biological Products's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangxi Institute of Biological Products Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jiangxi Institute of Biological Products's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Jiangxi Institute of Biological Products's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is one times the annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 21.38% mean?
Jiangxi Institute of Biological Products (HKSE:06915) has a Return-on-Tangible-Equity of 21.38% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Jiangxi Institute of Biological Products and its competitors. This is 10% above median its historical median of 19.44. Over the past decade, Jiangxi Institute of Biological Products' Return-on-Tangible-Equity has ranged from 15.36 to 21.38. According to the industry distribution chart, Jiangxi Institute of Biological Products ranks #182 out of 898 companies in the Drug Manufacturers industry, placing it in the top 20.3%.
Is Jiangxi Institute of Biological Products' Return-on-Tangible-Equity too high?
Jiangxi Institute of Biological Products' current Return-on-Tangible-Equity of 21.38% is 10% above median its 10-year median of 19.44. Over the past 10 years, this metric has ranged from a low of 15.36 to a high of 21.38. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.52. Jiangxi Institute of Biological Products' value of 21.38% is 184.5% above this industry median. Based on the distribution chart, Jiangxi Institute of Biological Products ranks #182 out of 898 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Jiangxi Institute of Biological Products has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Jiangxi Institute of Biological Products' Return-on-Tangible-Equity compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Jiangxi Institute of Biological Products ranks #182 out of 898 companies for Return-on-Tangible-Equity. This places Jiangxi Institute of Biological Products in the top 20% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.52. Jiangxi Institute of Biological Products' value of 21.38% is 184.5% above this benchmark. Historically, Jiangxi Institute of Biological Products' own Return-on-Tangible-Equity has ranged from 15.36 to 21.38 over the past decade. While the company's 10-year median is 19.44 vs. the industry median of 7.52, Jiangxi Institute of Biological Products has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.52, based on 898 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangxi Institute of Biological Products's current Return-on-Tangible-Equity of 21.38% is 184.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Jiangxi Institute of Biological Products and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangxi Institute of Biological Products's current Return-on-Tangible-Equity is 21.38%, which is 10% above median its own 10-year median of 19.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangxi Institute of Biological Products stock overvalued right now?
Jiangxi Institute of Biological Products (HKSE:06915) has a current Return-on-Tangible-Equity of 21.38%. The current Return-on-Tangible-Equity is 21.38%, which is 10% above median its 10-year median of 19.44 and 184.5% above the Drug Manufacturers industry median of 7.52. Jiangxi Institute of Biological Products' overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Jiangxi Institute of Biological Products (HKSE:06915), the current Return-on-Tangible-Equity is 21.38% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Jiangxi Institute of Biological Products Inc is principally engaged in the business of research and development, and production and sale of human tetanus antitoxin. It operates as the provider and exporter of Human TAT in China and an antiserum platform company. Its products include biological products containing immunoglobulins or immunoglobulin F(ab')2 fragments, which are used in medical applications such as tetanus, snakebite envenoming, and rabies treatment. The majority of the company's revenue is derived from the sale of Human Tetanus Antitoxin in the Chinese mainland.
23GF Score
Get the complete analysis for HKSE:06915
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06915 has been successfully added to your 
